Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May-Jun;31(3):303-306.
doi: 10.21873/invivo.11059.

The Effectiveness of Febrile Neutropenia Prophylaxis with Lipegfilgrastim in Routine Clinical Practice

Lubos Holubec  1   2 , Jiri Polivka  3   4   5 , Lenka Lisnerova  2 , Tereza Kubikova  1   4 , Martin Safanda  2
Affiliations
Review

The Effectiveness of Febrile Neutropenia Prophylaxis with Lipegfilgrastim in Routine Clinical Practice

Lubos Holubec et al. In Vivo. 2017 May-Jun.

Abstract

Febrile neutropenia (FN) is a common and potentially fatal complication of anticancer treatment, particularly in patients receiving myelosuppressive chemotherapy. It has been shown that prophylaxis with granulocyte colony-stimulating factor (G-CSF), especially its pegylated forms, significantly reduces the incidence of FN, the likelihood of chemotherapy dose intensity reduction and, also, the number of hospitalizations due to FN. This review discusses currently published results from clinical trials dealing with FN prophylaxis in routine clinical practice in patients with solid tumors and myeloproliferative malignancies with a focus on lipegfilgrastim, which is the newest modification of the original molecule filgrastim. The discussed results proved that prophylactic administration of lipegfilgrastim can almost eliminate the risk of FN and significantly reduce the risk of chemotherapy (CHT) dose reduction in routine clinical practice in cases of a clear high-risk chemotherapy regimen or in the presence of risk factors (such as age, comorbidities, performance status, etc.) in patients who received chemotherapy with medium risk of FN.

Keywords: Lipegfilgrastim; febrile neutropenia; myelosuppressive chemotherapy; prophylaxis; review.

PubMed Disclaimer

References

    1. Almenar CD, Bosch RC, Jiménez OE, Álvarez R, Cuervo JM, Díaz FN, Sánchez HAB, Galán B, Giner MV, Codes M, De Villena M, LEARN II Study Group. Effectiveness of daily versus non-daily granulocyte colony-stimulating factors in patients with solid tumours undergoing chemotherapy: A multivariate analysis of data from current practice. Eur J Cancer Care (Engl) 2013;22:400–412. - PMC - PubMed
    1. Shayne M, Crawford J, Dale DC, Culakova E, Lyman GH, ANC Study Group. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat. 2006;100:255–262. - PubMed
    1. Krzemieniecki K, Sevelda P, Erdkamp F, Smakal M, Schwenkglenks M, Puertas J, Trojan A, Szabo Z, Bendall K, Maenpaa J. Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy – findings from clinical practice. Support Care Cancer. 2014;22:667–677. - PMC - PubMed
    1. Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C, European Organisation for Research and Treatment of Cancer. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer Oxf Engl 1990. 2011;47:8–32. - PubMed
    1. Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: Systematic review and meta-analysis. BMC Cancer. 2011;11:404. - PMC - PubMed

MeSH terms

LinkOut - more resources